

## Is there a need for Govt action to provide FTO for Indian manufacturers?

Drug candidate	Strength of Patent barriers exist?	Valid active patents are NOT being worked in India (directly or via licensees) (Yes- 1; No-0)	Quantity being made available in India is NOT enough to meet Indian needs and affordable (Yes-1; No-0)	There are Indian manufacturers capable of (already making or prepared to) making this drug (Yes- 1; No-0)	Will Govt action be needed to provide FTO to Indian manufacturers (if drug proven important)?	SCORE: DRUG POTENTIAL (taken from Heat map - Drug Potential)	With current info available on drug, is it worthwhile for the GoI to take action to provide FTO for Indian manufacturers?	Drug candidate
<a href="#">Chloroquine</a>	0%	NA	NA	NA	0%	54%	None reqd	<a href="#">Chloroquine</a>
<a href="#">Hydroxychloroquine</a>	0%	NA	NA	NA	0%	54%	None reqd	<a href="#">Hydroxychloroquine</a>
<a href="#">Remdesivir</a>	100%	1	1	1	100%	Awaiting CT data	Await CT data	<a href="#">Remdesivir</a>
<a href="#">Lopinavir/Ritonavir</a>	0%	NA	NA	NA	0%	34%	None reqd	<a href="#">Lopinavir/Ritonavir</a>
<a href="#">Favipiravir</a>	50%	1	1	1	100%	73%	36%	<a href="#">Favipiravir</a>
<a href="#">Baloxavir Marboxil</a>	100%	1	1	1	100%	Awaiting CT data	Await CT data	<a href="#">Baloxavir Marboxil</a>
<a href="#">Darunavir</a>	0%	NA	NA	NA	0%	34%	None reqd	<a href="#">Darunavir</a>
<a href="#">Ribavirin + IFN beta</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Ribavirin + IFN beta</a>
<a href="#">Galidesivir</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Galidesivir</a>
<a href="#">Oseltamivir</a>	0%	NA	NA	NA	0%	34%	None reqd	<a href="#">Oseltamivir</a>
<a href="#">Umifenovir</a>	0%	NA	NA	NA	0%	42%	None reqd	<a href="#">Umifenovir</a>
<a href="#">Camostat mesylate</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Camostat mesylate</a>
<a href="#">Ruxolitinib</a>	100%	0	1	1	67%	Awaiting CT data	Await CT data	<a href="#">Ruxolitinib</a>
<a href="#">Interferon beta</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Interferon beta</a>
<a href="#">Tocilizumab</a>	0%	NA	NA	NA	0%	73%	None reqd	<a href="#">Tocilizumab</a>
<a href="#">Ustekinumab</a>	100%	1	1	1	100%	Awaiting CT data	Await CT data	<a href="#">Ustekinumab</a>
<a href="#">Nigericin</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Nigericin</a>
<a href="#">Teicoplanin</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Teicoplanin</a>
<a href="#">Ivermectin</a>	0%	NA	NA	NA	0%	Awaiting CT data	None reqd	<a href="#">Ivermectin</a>

Source: TFORD-COVID19-India (c) Venture Center, 2020